Revenue from operations jumped 43.16% to Rs 246.73 crore in Q2 FY25 as compared with Rs 172.35 crore in Q2 FY24.
Total expenses grew by 34.91% YoY to Rs 205.13 crore during the quarter. Employee benefit expenses was at Rs 19.63 crore (up 24.32% YoY while) Cost of material consumed stood at Rs 142.99 crore (down 3.31% YoY).
Profit before tax stood at Rs 50.04 crore in Q2 FY25 as compared with pre tax loss of Rs 9.94 crore posted in Q2 FY24.
EBITDA stood at Rs 48.9 crore in Q2 FY25, recording the growth of 97.18% as compared with Rs 24.8 crore in Q2 FY24. EBITDA margin improved by 19.8% during the quarter as compared with 14.4% posted in corresponding quarter last year.
Meanwhile, the inspection concluded by the Pharmaceuticals and Medical Devices Agency, Japan (PMDA), which revealed no critical or major observations, the agency has issued an Inspection result report declaring the Sachin Facility as compliant with good manufacturing practices (GMP).
Naresh Patel, executive chairman & managing director, Ami Organics, said, “Despite ongoing challenges in the global chemical industry, I am pleased to report stellar year-over-year growth of 43.2% in Q2FY25, driven by exceptional performance in our Pharmaceutical Intermediates and Specialty Chemicals businesses. Our key products maintained growth momentum, and an earlier-than-anticipated ramp-up in our CDMO business provided an additional boost to our results.
I am also proud to announce that PMDA Japan has issued an Inspection Result Report declaring our Sachin Facility as Good Manufacturing Practices (GMP) compliant. We are experiencing resurgence in demand for our core molecules, bolstered by ramp up in CDMO contract and strong volume growth within our Specialty Chemicals division. Based on the current order pipeline, we are raising our revenue growth guidance for FY25 from 25% to 30%.”
Ami Organics is engaged in business of drugs intermediate chemicals and related activities.